PMID- 38375723
OWN - NLM
STAT- MEDLINE
DCOM- 20240221
LR  - 20240221
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 28
IP  - 3
DP  - 2024 Feb
TI  - Bosentan and ambrisentan in the treatment of idiopathic pulmonary fibrosis: a 
      meta-analysis.
PG  - 1183-1193
LID - 35357 [pii]
LID - 10.26355/eurrev_202402_35357 [doi]
AB  - OBJECTIVE: The aim is to showcase the effectiveness and safety of bosentan or 
      ambrisentan in individuals diagnosed with idiopathic pulmonary fibrosis (IPF) and 
      offer fresh evidence for the management of this condition. MATERIALS AND METHODS: 
      For this research, we conducted a meta-analysis of randomized controlled trials 
      by searching various databases, including the Cochrane Library, Excerpta Medica 
      Database, PubMed, and Web of Science. The retrieval was conducted until November 
      2021. We analyzed the variances in 6-minute walk distance (6MWD), death, 
      diffusion capacity for carbon monoxide (DLCO), forced vital capacity (FVC), 
      hospitalization, IPF worsening, mean pulmonary arterial pressure, serious adverse 
      events (SAEs), Short Form-36 improved, and St. George's Respiratory Questionnaire 
      between the treatment and control groups. RESULTS: A sum of six studies involving 
      1,928 participants were found to meet the inclusion criteria. The quality of 
      evidence was high. The control group had significantly higher values for 6MWD, 
      DLCO, and FVC compared to the ambrisentan treatment group. The rates of 
      hospitalization and IPF worsening were considerably greater in comparison with 
      the control group. The bosentan group exhibited significantly reduced rates of 
      hospitalization and IPF worsening in comparison with the control group. Both 
      drugs did not cause any raising in death or SAEs when in comparison with the 
      control group. CONCLUSIONS: The findings of this research validate the 
      effectiveness and safety of bosentan for treating IPF patients. This medication 
      can enhance the quality of life for individuals with IPF without causing any 
      significant increase in SAEs. However, it does not have a notable influence on 
      the long-term prognosis. The findings of this research do not endorse the 
      utilization of ambrisentan in individuals diagnosed with IPF.
FAU - Li, H-F
AU  - Li HF
AD  - Department of Cardiovascular Medicine, Affiliated Hospital (Clinical College) of 
      Xiangnan University, Chenzhou, Hunan, China. zhxl_19@163.com.
FAU - Wang, J-X
AU  - Wang JX
FAU - Xie, Z-F
AU  - Xie ZF
FAU - Li, L-H
AU  - Li LH
FAU - Li, B
AU  - Li B
FAU - Huang, F-F
AU  - Huang FF
FAU - Li, J
AU  - Li J
FAU - Zhou, X-L
AU  - Zhou XL
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - Q326023R30 (Bosentan)
RN  - HW6NV07QEC (ambrisentan)
RN  - 0 (Phenylpropionates)
RN  - 0 (Pyridazines)
SB  - IM
MH  - Humans
MH  - Bosentan/therapeutic use
MH  - Quality of Life
MH  - *Idiopathic Pulmonary Fibrosis/drug therapy
MH  - *Phenylpropionates/adverse effects
MH  - *Pyridazines
EDAT- 2024/02/20 11:50
MHDA- 2024/02/21 11:22
CRDT- 2024/02/20 05:33
PHST- 2024/02/21 11:22 [medline]
PHST- 2024/02/20 11:50 [pubmed]
PHST- 2024/02/20 05:33 [entrez]
AID - 35357 [pii]
AID - 10.26355/eurrev_202402_35357 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2024 Feb;28(3):1183-1193. doi: 
      10.26355/eurrev_202402_35357.